Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
138.88
-3.70 (-2.60%)
Jun 27, 2025, 4:00 PM - Market closed
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Krystal Biotech stock ranges from a low of $155 to a high of $245. The average analyst price target of $211.13 forecasts a 52.02% increase in the stock price over the next year.
Price Target: $211.13 (+52.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 | Strong Buy | Reiterates | $240 | +72.81% | Jun 24, 2025 |
| Citigroup | Citigroup | Hold Maintains $215 → $155 | Hold | Maintains | $215 → $155 | +11.61% | May 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $195 → $189 | Strong Buy | Maintains | $195 → $189 | +36.09% | May 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $219 | Strong Buy | Maintains | $219 | +57.69% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 | Strong Buy | Reiterates | $240 | +72.81% | May 6, 2025 |
Financial Forecast
Revenue This Year
418.49M
from 290.52M
Increased by 44.05%
Revenue Next Year
611.61M
from 418.49M
Increased by 46.15%
EPS This Year
5.99
from 3.00
Increased by 99.65%
EPS Next Year
9.43
from 5.99
Increased by 57.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 470.4M | 803.8M | 1.1B | ||
| Avg | 418.5M | 611.6M | 849.9M | ||
| Low | 361.5M | 412.4M | 692.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 61.9% | 92.1% | 87.4% | ||
| Avg | 44.1% | 46.1% | 39.0% | ||
| Low | 24.4% | -1.5% | 13.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.39 | 14.88 | 23.91 | ||
| Avg | 5.99 | 9.43 | 13.27 | ||
| Low | 4.48 | 6.17 | 8.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 179.7% | 148.4% | 153.6% | ||
| Avg | 99.6% | 57.4% | 40.7% | ||
| Low | 49.3% | 3.1% | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.